Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Journal of the National Cancer Institute

• Publication date

  2025-12-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djaf344PMID 41418409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan

  2025cited by this paper
• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

  2024cited by this paper
• Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer with a High Sensitivity Assay.

  2024cited by this paper
• Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

  2024cited by this paper
• Cancer statistics, 2024

  2024cited by this paper
• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

  2023cited by this paper
• Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology

  2023cited by this paper
• Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.

  2023cited by this paper
• Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer

  2023cited by this paper
• Discordance of HER2 Expression and/or Amplification on Repeat Testing.

  2023cited by this paper
• Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology

  2022cited by this paper
• Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.

  2022cited by this paper
• Trastuzumab Deruxtecan in HER2-Low Breast Cancer.

  2022cited by this paper
• Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer

  2022cited by this paper
• Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

  2022cited by this paper
• Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

  2022cited by this paper
• Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status

  2022cited by this paper
• Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus

  2021cited by this paper
• Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin

  2020cited by this paper
• Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer

  2020cited by this paper
• Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival.

  2020cited by this paper
• Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma

  2019cited by this paper
• Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

  2019cited by this paper
• Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

  2018cited by this paper
• PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer

  2017cited by this paper
• DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

  2016cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

  2012cited by this paper
• Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.

  2012cited by this paper
• Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.

  2011cited by this paper
• Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

  2009cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

  2006cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

  2002cited by this paper
• Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.

  2002cited by this paper
• Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.

  2001cited by this paper

• No citing papers are available for this paper.